Compare Neurocrine Biosciences Inc (NBIX) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs First Trust Cloud Computing ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while First Trust Cloud Computing ETF trades at $174.89 (market cap $3.47B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.1× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and First Trust Cloud Computing ETF for 85 Days on average.
| NBIX | SKYY | |
|---|---|---|
Market Cap | $14.36B | $3.47B |
Volume | 1,237,180 | 176,159 |
Sector | Health | — |
52-Week High | $185.50 | $171.01 |
52-Week Low | $123.10 | $104.16 |
Typical Hold Time | 23 Days | 85 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
SKYY (First Trust Cloud Computing ETF) trades at $174.885, up 2.4% with strong bullish technical signals from moving averages. The ETF recently hit a 52-week high, benefiting from AI-driven cloud computing demand. Technical indicators show bullish momentum with support at $169 and resistance at $171. The fund provides diversified exposure to cloud infrastructure and software companies without heavy concentration in mega-cap tech stocks.
The outlook remains positive as cloud computing benefits from secular trends including AI adoption and digital transformation. Key risks include sector concentration and market volatility. Institutional activity shows mixed sentiment with some firms trimming positions while broader analyst coverage highlights the ETF's strategic positioning in the growing cloud computing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
